ArticleAntimicrobial agents and chemotherapy2026
Efficacy of cefiderocol and levofloxacin against
Waki Imoto, Junko Abe, Norihiro Sakurai, Kengo Kawamoto, Koichi Yamada, Yukihiro Kaneko, Hiroshi Kakeya
Abstract read
In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Waki ImotoDepartment of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.ORCID 0000-0003-0392-1764 Junko AbeDepartment of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Norihiro SakuraiDepartment of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Kengo KawamotoDepartment of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Koichi YamadaDepartment of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yukihiro KanekoResearch Center for Infectious Disease Sciences (RCIDS), Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Hiroshi KakeyaDepartment of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Funding
Japanese Society for Chemotherapy 70th Anniversary Research Support ProgramJapan Society for the Promotion of Science 24K11659Morinomiyako Medical Research Foundation 2021-01-02Takeda Science Foundation 2024047731
6 · The paper itselfAbstract
Cefiderocol (CFDC) is a promising drug for treating infections caused by
Indexed as
Anti-Bacterial AgentsCephalosporinsGram-Negative Bacterial InfectionsHemorrhageLevofloxacinPneumonia, BacterialStenotrophomonas maltophiliaAnimalsBacterial LoadCefiderocolDisease Models, AnimalLungMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsCefiderocolCephalosporinsLevofloxacincefiderocolhemorrhagic pneumonialevofloxacinmouse modelStenotrophomonas maltophilia
Identifiers
PMID41616262
PMCPMC12959135
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390